Immune checkpoint blockade induced sarcoid-like reaction mimicking progression of disease in a patient with microsatellite instable colorectal cancer: Case report and review of the literature Journal Article


Authors: Keane, F.; Yogiaveetil, E.; Kezlarian, B.; Lagratta, M.; Segal, N. H.; Abou-Alfa, G.; O'Reilly, E. M.; Saltz, L.; Dika, I. E.
Article Title: Immune checkpoint blockade induced sarcoid-like reaction mimicking progression of disease in a patient with microsatellite instable colorectal cancer: Case report and review of the literature
Abstract: Background: Oncologists are prescribing checkpoint inhibitors with greater frequency, and an awareness of and ability to recognize immune-related adverse events (irAEs) is a key part of the safe administration of these drugs. Case Description: Herein, we report the case of a 26-year-old male diagnosed with de novo metastatic right-sided colon cancer to the liver, with tumor immunohistochemistry demonstrating loss of MSH2 and MSH6, and a pathogenic mutation in MSH2 identified on germline testing, consistent with Lynch Syndrome. The patient received first-line treatment with pembrolizumab. Following 7 months of immune checkpoint blockade (ICB), new pulmonary findings on routine imaging were felt to be concerning for disease progression, despite ongoing excellent clinical status, disease control in the liver, and stable tumor markers. An endobronchial biopsy of one of the mediastinal lymph nodes demonstrated granulomatous inflammation consistent histologically with sarcoidosis, and a diagnosis of sarcoid-like reaction (SLR) secondary to immunotherapy was established. Pembrolizumab was discontinued, and the patient continued active monitoring off of active therapy, with durable cancer control. After 8 months of watchful waiting, new hepatic lesions and increasing abdomino-pelvic lymphadenopathy were identified on imaging, concerning for progression of disease. Inguinal lymph node biopsy demonstrated findings consistent with ongoing SLR. The patient remains with durable cancer control, now 24 months since receipt of ICB. In addition, he remains asymptomatic of the SLR. Conclusions: This case highlights the propensity of SLRs to imitate progression of disease, and the importance of awareness of this adverse effect, to prompt appropriate investigation and management. © Journal of Gastrointestinal Oncology. All rights reserved.
Keywords: immunohistochemistry; adult; clinical article; human tissue; case report; drug withdrawal; follow up; colorectal cancer; cancer immunotherapy; carcinoembryonic antigen; liver metastasis; watchful waiting; microsatellite instability; inguinal lymph node; cancer control; disease control; loss of function mutation; colon adenocarcinoma; sarcoidosis; lynch syndrome; protein msh6; disease exacerbation; lymph node biopsy; mediastinum lymph node; programmed death 1 receptor; granulomatous inflammation; first-line treatment; high throughput sequencing; human; male; article; pembrolizumab; multidisciplinary team; x-ray computed tomography; bronchus biopsy; dna mismatch repair protein msh2; immune checkpoint blockade (icb); sarcoid-like reaction (slr)
Journal Title: Journal of Gastrointestinal Oncology
Volume: 15
Issue: 1
ISSN: 2078-6891
Publisher: Pioneer Bioscience Publishing Company  
Date Published: 2024-02-29
Start Page: 500
End Page: 507
Language: English
DOI: 10.21037/jgo-23-435
PROVIDER: scopus
PMCID: PMC10932687
PUBMED: 38482249
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Leonard B Saltz
    791 Saltz
  2. Neil Howard Segal
    210 Segal
  3. Ghassan Abou-Alfa
    570 Abou-Alfa
  4. Eileen O'Reilly
    789 O'Reilly
  5. Fergus Keane
    30 Keane